The Association of IL28B Polymorphism and Graft Survival in Patients with Hepatitis C Undergoing Liver Transplantation

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Allam, Sridhar R ^a   Krüger, Bernd ^b   Mehrotra, Anita ^a   Schiano, Thomas ^a   Schröppel, Bernd ^a   Murphy, Barbara ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; INTERLEUKIN 28B;

ADULT; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DONOR; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HUMAN; HUMAN TISSUE; INTERLEUKIN 28B GENE; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RECURRENT DISEASE; SURVIVAL TIME;

FEMALE; GENE EXPRESSION; GENOTYPE; GRAFT SURVIVAL; HEPATITIS C; HUMANS; INTERLEUKINS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECURRENCE; TIME FACTORS;

EID: 84873857247     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054854     Document Type: Article

References (31)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, et al. (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: 705-714.
2. Thuluvath PJ, Krok KL, Segev DL, Yoo HY, (2007) Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl 13: 719-724.
3. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, et al. (2008) Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 8: 2426-2433.
4. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
5. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
6. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al. (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138: 1338-1345, 1345 e1331-1337.
7. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, et al. (2010) Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 139: 1577-1585, 1585 e1571-1573.
8. Lange CM, Moradpour D, Doehring A, Lehr HA, Mullhaupt B, et al. (2011) Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 55: 322-327.
9. Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, et al. (2011) Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53: 317-324.
10. Coto-Llerena M, Perez-Del-Pulgar S, Crespo G, Carrion JA, Martinez SM, et al. (2011) Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 11: 1051-1057.
11. Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt KD, et al. (2012) The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation 94: 197-203.
12. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, et al. (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63-68.
13. Mihm S, Frese M, Meier V, Wietzke-Braun P, Scharf JG, et al. (2004) Interferon type I gene expression in chronic hepatitis C. Lab Invest. 84: 1148-1159.
14. Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, et al. (2011) IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 55: 289-298.
15. Fox BA, Sheppard PO, O'Hara PJ, (2009) The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family. PLoS One 4: e4933.
16. Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, et al. (2009) Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 113: 5868-5877.
17. Cisneros E, Banos I, Citores MJ, Duca A, Salas C, et al. (2012) Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860. Transplantation 94: 275-280.
18. Kemmer N, Secic M, Zacharias V, Kaiser T, Neff GW, (2007) Long-term analysis of primary nonfunction in liver transplant recipients. Transplant Proc 39: 1477-1480.
19. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ, (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19: 1513-1520.
20. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 41: 1105-1109.
21. Rodriguez S, Gaunt TR, Day IN, (2009) Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169: 505-514.
22. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, et al. (2001) A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 234: 384-393; discussion 393-384.
23. Rauch A, Gaudieri S, Thio C, Bochud PY, (2009) Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 10: 1819-1837.
24. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, et al. (2010) A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 139: 1586-1592, 1592 e1581.
25. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 52: 1888-1896.
26. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, et al. (2010) Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 139: 499-509.
27. Shebl FM, Maeder D, Shao Y, Prokunina-Olsson L, Schadt EE, et al. (2010) In the absence of HCV infection, interferon stimulated gene expression in liver is not associated with IL28B genotype. Gastroenterology 139: 1422-1424.
28. Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, et al. (2011) Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 17: 289-298.
29. Klein I, Cornejo JC, Polakos NK, John B, Wuensch SA, et al. (2007) Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages. Blood 110: 4077-4085.
30. Coto-Llerena M, Crespo G, Gonzalez P, Koutsoudakis G, Miquel R, et al. (2012) Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. J Hepatol 56: 355-358.
31. U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. 2008 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998-2007: 2008.